A new drug to treat advanced prostate cancer has been made by Johnson & Johnson’s called Zytiga. In the small clinical trial of six months treatment, the drug nearly eliminated tumors in about one third of men whose disease had not yet spread beyond the prostate gland but was considered likely to do so.
Researchers show that bladder cancer and breast cancer patients whose tumors are eliminated before an operation tend to live longer. The prostate study is one of more than 4,500 that will be presented at the oncology society’s annual meeting in Chicago in early June. Another drug called Xalkori also could help some children with aggressive cancers by another study.
Xalkori also known as crizotinib was approved in last August to treat the roughly 5 percent of non-small-cell lung cancer cases. The new study shows that the drug also works in some childhood cancers with the same abnormal gene, particularly anaplastic large-cell lymphoma, neuroblastoma and inflammatory myofibroblastic tumors. Seven of eight children with anaplastic large-cell lymphoma had no detectable tumors after treatment.
The Zytiga was approved in April 2011 for use by men that effect with prostate cancer and who have tried the chemotheraphy drug docetaxel.
Reference :- New York Times